Press Releases

Oxford Biomedica notes Homology Medicines’ quarterly report and confirms financials for Oxford Biomedica Solutions LLC are in line with expectations

Oxford, UK – 16 August 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the release of Homology Medicines’ (“Homology”) quarterly report for the three months ended 30 June 2022. Financial information on Oxford Biomedica Solutions LLC (“Oxford Biomedica Solutions”) contained… Read More

Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy

Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies. The… Read More

Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology

Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology. As part of the project, Oxford Biomedica’s LentiStable™ technology platform… Read More

Oxford Biomedica expands Agreement with Juno Therapeutics, a Bristol Myers Squibb company; adding two new viral vector programmes for Bristol Myers Squibb CAR-T therapies

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More

Oxford Biomedica signs new three year agreement with AstraZeneca

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More

Oxford Biomedica notes announcement that FDA has lifted clinical hold on Homology Medicines’ pheNIX trial

Oxford, UK – 14 June 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the recent announcement from Homology Medicines Inc. (Nasdaq: FIXX) (“Homology”), a genetic medicines company regarding the pheNIX gene therapy trial. The U.S. Food and Drug Administration (FDA)… Read More

Oxford Biomedica Solutions announces novel Dual Plasmid Transfection System, and has demonstrated suspension bioreactor titres above E15 vg/L, and chromatography purification achieving 90% fully in-tact vector

Bedford, Massachusetts – May 6, 2022: Oxford Biomedica Solutions, LLC. (“Oxford Biomedica Solutions”), a new high-performing, full scope AAV manufacturing and innovation business, now offering its ‘Plug & Play’ Platform that has successfully delivered four GMP programs and five Investigational New Drug submissions. Oxford Biomedica Solutions is announcing today that… Read More

2021 Annual report and accounts & AGM notification

London, UK – 27 April 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “the Company” or “the Group”), a leading gene and cell therapy group, gives notice that copies of the 2021 Annual report and accounts and the… Read More

Preliminary results for the year ended 31 December 2021

Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading cell and gene therapy group, today announces its preliminary results for the year ended 31 December 2021. Dr. Roch Doliveux, Chair and Interim Chief Executive Officer of Oxford Biomedica, said: “I… Read More

Oxford Biomedica Appoints Namrata P Patel as Non-Executive Director

Oxford, UK – 13 April 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, announces the appointment of Ms. Namrata P Patel to the Board as an Independent Non-Executive Director with immediate effect. Ms. Patel has extensive international experience in manufacturing and end… Read More

Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology

Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or the “Company”), a leading gene and cell therapy group, is pleased to announce that it has completed… Read More

Oxford Biomedica announces that Sio Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease

This is a partner product. Visit the relevant partner website for further information. Read More

Press Releases

News from the year: /2015